37.00
Legend Biotech Corp Adr stock is traded at $37.00, with a volume of 1.18M.
It is down -1.15% in the last 24 hours and down -1.31% over the past month.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
See More
Previous Close:
$37.43
Open:
$37.42
24h Volume:
1.18M
Relative Volume:
0.70
Market Cap:
$6.80B
Revenue:
$520.18M
Net Income/Loss:
$-348.13M
P/E Ratio:
-19.27
EPS:
-1.92
Net Cash Flow:
$-176.18M
1W Performance:
-4.64%
1M Performance:
-1.31%
6M Performance:
+4.58%
1Y Performance:
-34.99%
Legend Biotech Corp Adr Stock (LEGN) Company Profile
Name
Legend Biotech Corp Adr
Sector
Industry
Phone
-
Address
-
Compare LEGN with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
LEGN
Legend Biotech Corp Adr
|
37.00 | 6.93B | 520.18M | -348.13M | -176.18M | -1.92 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
![]()
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Legend Biotech Corp Adr Stock (LEGN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Oct-08-24 | Initiated | Redburn Atlantic | Buy |
Jun-17-24 | Initiated | Truist | Buy |
May-24-24 | Reiterated | H.C. Wainwright | Buy |
May-23-24 | Initiated | Deutsche Bank | Buy |
Apr-17-24 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
Apr-03-24 | Initiated | Cantor Fitzgerald | Overweight |
Mar-13-24 | Initiated | Raymond James | Outperform |
Dec-19-23 | Initiated | Scotiabank | Sector Perform |
Nov-06-23 | Initiated | Goldman | Buy |
May-25-23 | Initiated | William Blair | Mkt Perform |
May-22-23 | Initiated | Daiwa Securities | Buy |
Mar-29-23 | Initiated | H.C. Wainwright | Buy |
Mar-24-23 | Initiated | RBC Capital Mkts | Outperform |
Dec-06-22 | Initiated | UBS | Buy |
Nov-02-22 | Initiated | Evercore ISI | Outperform |
Nov-01-22 | Initiated | Cowen | Outperform |
Oct-31-22 | Initiated | Guggenheim | Neutral |
Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
Mar-15-22 | Initiated | Barclays | Overweight |
Jan-31-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Jan-06-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Dec-21-21 | Initiated | Piper Sandler | Overweight |
May-18-21 | Initiated | BTIG Research | Buy |
Jul-01-20 | Initiated | JP Morgan | Overweight |
Jul-01-20 | Initiated | Jefferies | Buy |
Jun-30-20 | Initiated | Morgan Stanley | Overweight |
View All
Legend Biotech Corp Adr Stock (LEGN) Latest News
XTX Topco Ltd Takes $307,000 Position in Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) - Defense World
Legend Biotech on Track for Record Losing Streak — Data Talk - Morningstar
Cantor Fitzgerald Estimates Legend Biotech FY2025 Earnings - Defense World
Brokerages Set Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Price Target at $73.33 - Defense World
Bank of New York Mellon Corp Has $4.55 Million Stake in Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) - Defense World
HC Wainwright Forecasts Legend Biotech Q2 Earnings - Defense World
Legend Biotech’s (LEGN) Buy Rating Reiterated at HC Wainwright - Defense World
Q1 EPS Estimates for Legend Biotech Raised by HC Wainwright - Defense World
Legend Biotech (LEGN) Surges 6.0%: Is This an Indication of Further Gains? - Yahoo Finance
Legend Biotech’s SWOT analysis: stock poised for growth amid challenges By Investing.com - Investing.com India
Legend Biotech’s SWOT analysis: stock poised for growth amid challenges - Investing.com
H.C. Wainwright reiterates Buy rating on Legend Biotech stock after strong CARVYKTI sales - Investing.com India
Goldman Sachs reiterates buy rating on Legend Biotech stock after strong Carvykti sales - Investing.com India
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Shares Acquired by GAMMA Investing LLC - Defense World
Legend Biotech stock price target lowered to $54 at UBS on growth concerns - Investing.com
Legend Biotech stock maintains Buy rating as FDA eases CARVYKTI restrictions - Investing.com
Legend Biotech’s SWOT analysis: carvykti’s strong performance drives stock potential By Investing.com - Investing.com South Africa
Legend Biotech’s SWOT analysis: carvykti’s strong performance drives stock potential - Investing.com India
Legend Biotech to Host Investor Event During the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - Barchart.com
Oracle and GameStop Headline Market Cap Stock Movers on Thursday By Investing.com - Investing.com South Africa
Eli Lilly, General Electric among Tuesday’s market cap stock movers By Investing.com - Investing.com India
Eli Lilly, General Electric among Tuesday’s market cap stock movers - Investing.com
CARVYKTI shows lasting impact in multiple myeloma treatment By Investing.com - Investing.com South Africa
RBC Capital maintains outperform rating on Legend Biotech stock By Investing.com - Investing.com South Africa
RBC Capital maintains outperform rating on Legend Biotech stock - Investing.com India
BMO Capital reaffirms outperform rating on Legend Biotech stock By Investing.com - Investing.com South Africa
BMO Capital reaffirms outperform rating on Legend Biotech stock - Investing.com India
Legend Biotech’s SWOT analysis: carvykti drives growth as stock faces competition - Investing.com India
RBC Capital maintains Legend Biotech at outperform with $78 target By Investing.com - Investing.com South Africa
RBC Capital maintains Legend Biotech at outperform with $78 target - Investing.com
AbbVie, Nvidia, and Exelixis Lead Market Cap Stock Movers on Wednesday By Investing.com - Investing.com South Africa
AbbVie, Nvidia, and Exelixis Lead Market Cap Stock Movers on Wednesday - Investing.com
Legend Biotech stock holds $62 target, solid Carvykti sales growth - Investing.com India
Legend Biotech stock holds $62 target, solid Carvykti sales growth By Investing.com - Investing.com UK
Truist cuts Legend Biotech stock target to $71, maintains buy rating - Investing.com India
Raymond James maintains Legend Biotech Outperform rating - Investing.com
Raymond James maintains Legend Biotech Outperform rating By Investing.com - Investing.com UK
Earnings call transcript: Legend Biotech Q1 2025 sees strong CARVICTI sales boost - Investing.com India
Legend Biotech Q1 2025 slides: CARVYKTI sales surge 135% as path to profitability clarifies - Investing.com India
Legend Biotech Reports First Quarter 2025 Results and Recent Highlights - GlobeNewswire Inc.
Stock Surge: Legend Biotech Corp ADR (LEGN) Closes at 31.37, Marking a -6.08 Increase/Decrease - DWinneX
What Makes Legend Biotech (LEGN) a New Buy Stock - Yahoo Finance
Wall Street Analysts Think Legend Biotech (LEGN) Could Surge 135.16%: Read This Before Placing a Bet - Yahoo Finance
Top investors say Legend Biotech Corp ADR (LEGN) ticks everything they need - Sete News
LEGN stock rated a Buy by Redburn Atlantic - knoxdaily.com
Taking a look at what insiders are doing to gauge the Legend Biotech Corp ADR (LEGN)’s direction - knoxdaily.com
Selling Buzz: Graphjet Technology [GTI] 10% Owner SURIA SUKSES ENGINEERING SDN B sells 2,490,517 shares of the company – Knox Daily - knoxdaily.com
UP Fintech Holding Ltd ADR [TIGR] Records 200-Day SMA of $6.22 - knoxdaily.com
UEC Stock Sees Surge of Approximately 9.34% in Last Five Days - knoxdaily.com
Vir Biotechnology Inc [VIR] Records 200-Day SMA of $8.24 - knoxdaily.com
Arm Holdings plc. ADR [ARM] Officer makes an insider purchase of 9,220 shares worth 1.41 million. - knoxdaily.com
Legend Biotech Corp Adr Stock (LEGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):